Component

Progression-free survival in high-grade glioma

Progression-free survival in high-grade glioma. Species, exposure and limitations are retained in each linked claim.

3 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. Confirmed objective response rate was 10% with one complete and two partial responses, median progression-free survival was 2.6 months and median overall survival was 11.1 months, prior immunotherapy negatively influenced overall survival with a hazard ratio of 2.95, and the combination of Imprime and pembrolizumab is tolerable but did not improve the outcome of advanced stage non-small cell lung cancer patients who previously progressed on anti-PD-1 or PD-L1 immunotherapies.

    Imprime PGG / BTH1677, a soluble yeast beta-(1->3)/(1->6)-glucan → Progression-free survival in high-grade glioma source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/glucan-research/39670007.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "2aad97fa3dcbfbdcedfc88a4fbcad902de0cbade16dcf3c94b26a9c6960ced38", "start_char": 0, "end_char": 2076, "text_sha256": "2aad97fa3dcbfbdcedfc88a4fbcad902de0cbade16dcf3c94b26a9c6960ced38"}
    experimental_model
    Investigator-initiated multi-institutional single-arm phase Ib/II trial in previously treated patients
    exposure
    Imprime PGG at the 4 milligram per kilogram maximum tolerated dose with pembrolizumab
    limitations
    Single-arm with no randomised comparator, in patients who had already progressed on checkpoint blockade. Thirty patients were evaluable for efficacy.
    nutrient_topic
    Beta-glucan research collection; topical membership is not evidence of a direct clinical effect, and each preparation is recorded as its own entity with no family link joining any pair. · Beta-glucan
    organism
    Human
    plain_language
    Added to a checkpoint drug in patients who had already failed one, it did not help.
    primary_references
    [bg-p39670007] Phase Ib/II study of imprime PGG and pembrolizumab in patients with previously treated advanced non-small cell lung cancer (NSCLC): BTCRC LUN 15-017. (2024). https://pubmed.ncbi.nlm.nih.gov/39670007/ DOI: 10.21037/tlcr-24-346
    tissue_or_cell_type
    Advanced non-small cell lung cancer

    Beta-glucan: a structural family rather than an agent, what decides whether a bound glucan actually signals, the complement route that a cereal and a yeast preparation share, and the unequal human evidence behind each (2026-09-22) · lines 333–344

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Investigator-initiated multi-institutional single-arm phase Ib/II trial in previously treated patients · source_derived_draft · unverified_draft

    ### bg-no-benefit-with-pembrolizumab Confirmed objective response rate was 10% with one complete and two partial responses, median progression-free survival was 2.6 months and median overall survival was 11.1 months, prior immunotherapy negatively influenced overall survival with a hazard ratio of 2.95, and the combination of Imprime and pembrolizumab is tolerable but did not improve the outcome of advanced stage non-small cell lung cancer patients who previously progressed on anti-PD-1 or PD-L1 immunotherapies. Condition category: normal nutrient_topic: Beta-glucan research collection; topical membership is not evidence of a direct clinical effect, and each preparation is recorded as its own entity with no family link joining any pair. plain_language: Added to a checkpoint drug in patients who had already failed one, it did not help. organism: Human tissue_or_cell_type: Advanced non-small cell lung cancer experimental_model: Investigator-initiated multi-institutional single-arm phase Ib/II trial in previously treated patients limitations: Single-arm with no randomised comparator, in patients who had already progressed on checkpoint blockade. Thirty patients were evaluable for efficacy. exposure: Imprime PGG at the 4 milligram per kilogram maximum tolerated dose with pembrolizumab evidence_span: {"source_cache": "artifacts/glucan-research/39670007.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "2aad97fa3dcbfbdcedfc88a4fbcad902de0cbade16dcf3c94b26a9c6960ced38", "start_char": 0, "end_char": 2076, "text_sha256": "2aad97fa3dcbfbdcedfc88a4fbcad902de0cbade16dcf3c94b26a9c6960ced38"} [bg-p39670007] Phase Ib/II study of imprime PGG and pembrolizumab in patients with previously treated advanced non-small cell lung cancer (NSCLC): BTCRC LUN 15-017. (2024). https://pubmed.ncbi.nlm.nih.gov/39670007/ DOI: 10.21037/tlcr-24-346
    Complete structured claim and evidence

  2. Kaplan-Meier analysis showed a 21-month median overall survival with 41.7% of patients alive at 2 years and 25% at 3 and 4 years, and median progression-free survival from diagnosis was 13.1 months for 17 patients taking more than one month of mebendazole against 9.2 months for 7 patients who received less than one month, with the authors concluding that further studies are needed to determine efficacy in malignant glioma.

    Mebendazole → Progression-free survival in high-grade glioma source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/mebendazole-research/33506200.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "ab5f2c1d14ccb7fa9f690201326bdbfcab3e07758bc78b76ff9adec2ca774ec6", "start_char": 0, "end_char": 1712, "text_sha256": "ab5f2c1d14ccb7fa9f690201326bdbfcab3e07758bc78b76ff9adec2ca774ec6"}
    experimental_model
    Single-centre dose-escalation and safety study in 24 patients with newly diagnosed high-grade glioma
    exposure
    Oral mebendazole at 25, 50, 100 and 200 milligrams per kilogram per day with adjuvant temozolomide, with trough plasma levels at 4, 8 and 16 weeks
    limitations
    The only human oncology record here. It is a single-arm dose-escalation and safety study without a control group, so the survival figures cannot be read as efficacy.
    nutrient_topic
    Mebendazole research collection; topical membership is not evidence of a direct clinical effect, and mebendazole is recorded separately from albendazole, from the benzimidazole class and from its own crystal forms. · Mebendazole
    organism
    Human
    plain_language
    Patients who stayed on it longer did better, but there was no control group and staying on a drug longer is itself a sign of doing well.
    primary_references
    [mbz-p33506200] Mebendazole and temozolomide in patients with newly diagnosed high-grade gliomas: results of a phase 1 clinical trial. (2021). https://pubmed.ncbi.nlm.nih.gov/33506200/ DOI: 10.1093/noajnl/vdaa154
    tissue_or_cell_type
    Brain

    Mebendazole: the tubulin it binds, why that is selective, the crystal form that decides whether any of it works, and the off-target that became an oncology programme (2026-09-22) · lines 589–600

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Single-centre dose-escalation and safety study in 24 patients with newly diagnosed high-grade glioma · source_derived_draft · unverified_draft

    ### mbz-uncontrolled-survival-figures Kaplan-Meier analysis showed a 21-month median overall survival with 41.7% of patients alive at 2 years and 25% at 3 and 4 years, and median progression-free survival from diagnosis was 13.1 months for 17 patients taking more than one month of mebendazole against 9.2 months for 7 patients who received less than one month, with the authors concluding that further studies are needed to determine efficacy in malignant glioma. Condition category: normal nutrient_topic: Mebendazole research collection; topical membership is not evidence of a direct clinical effect, and mebendazole is recorded separately from albendazole, from the benzimidazole class and from its own crystal forms. plain_language: Patients who stayed on it longer did better, but there was no control group and staying on a drug longer is itself a sign of doing well. organism: Human tissue_or_cell_type: Brain experimental_model: Single-centre dose-escalation and safety study in 24 patients with newly diagnosed high-grade glioma limitations: The only human oncology record here. It is a single-arm dose-escalation and safety study without a control group, so the survival figures cannot be read as efficacy. exposure: Oral mebendazole at 25, 50, 100 and 200 milligrams per kilogram per day with adjuvant temozolomide, with trough plasma levels at 4, 8 and 16 weeks evidence_span: {"source_cache": "artifacts/mebendazole-research/33506200.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "ab5f2c1d14ccb7fa9f690201326bdbfcab3e07758bc78b76ff9adec2ca774ec6", "start_char": 0, "end_char": 1712, "text_sha256": "ab5f2c1d14ccb7fa9f690201326bdbfcab3e07758bc78b76ff9adec2ca774ec6"} [mbz-p33506200] Mebendazole and temozolomide in patients with newly diagnosed high-grade gliomas: results of a phase 1 clinical trial. (2021). https://pubmed.ncbi.nlm.nih.gov/33506200/ DOI: 10.1093/noajnl/vdaa154
    Complete structured claim and evidence

Where it participates (unsigned role)

  1. Objective response rate based on blinded central radiology review was higher in the BTH1677 arm versus control but the difference between groups was not statistically significant at 60.4% versus 43.5% with P = .2096, all other clinical endpoints also favoured the BTH1677 arm but none statistically differed between arms, and although a higher incidence of Grade 3 or 4 adverse events occurred in the BTH1677 versus control arm at 93.2% versus 66.7% no unexpected adverse events were observed while serious adverse events and discontinuations due to adverse events were lower.

    Imprime PGG / BTH1677, a soluble yeast beta-(1->3)/(1->6)-glucan → Objective tumour response rate source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/glucan-research/29486797.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "7e4ff586490d7fdbefa5e817f7ee8b59c72e666bfb473620331f2fb178f46789", "start_char": 0, "end_char": 2024, "text_sha256": "7e4ff586490d7fdbefa5e817f7ee8b59c72e666bfb473620331f2fb178f46789"}
    experimental_model
    Randomised controlled phase II trial with blinded central radiology review as the primary read
    exposure
    BTH1677 4 milligrams per kilogram weekly with bevacizumab, carboplatin and paclitaxel against the same backbone alone
    limitations
    Ninety-two patients randomised 61 to 31, with response read centrally. A higher rate of grade 3 or 4 adverse events occurred on the glucan arm.
    nutrient_topic
    Beta-glucan research collection; topical membership is not evidence of a direct clinical effect, and each preparation is recorded as its own entity with no family link joining any pair. · Beta-glucan
    organism
    Human
    plain_language
    A second trial pointed the same way on every measure and reached statistical significance on none of them.
    primary_references
    [bg-p29486797] A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer. (2018). https://pubmed.ncbi.nlm.nih.gov/29486797/ DOI: 10.1186/s40425-018-0324-z
    tissue_or_cell_type
    Untreated advanced non-small cell lung cancer

    Beta-glucan: a structural family rather than an agent, what decides whether a bound glucan actually signals, the complement route that a cereal and a yeast preparation share, and the unequal human evidence behind each (2026-09-22) · lines 320–331

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomised controlled phase II trial with blinded central radiology review as the primary read · source_derived_draft · unverified_draft

    ### bg-second-trial-not-significant Objective response rate based on blinded central radiology review was higher in the BTH1677 arm versus control but the difference between groups was not statistically significant at 60.4% versus 43.5% with P = .2096, all other clinical endpoints also favoured the BTH1677 arm but none statistically differed between arms, and although a higher incidence of Grade 3 or 4 adverse events occurred in the BTH1677 versus control arm at 93.2% versus 66.7% no unexpected adverse events were observed while serious adverse events and discontinuations due to adverse events were lower. Condition category: normal nutrient_topic: Beta-glucan research collection; topical membership is not evidence of a direct clinical effect, and each preparation is recorded as its own entity with no family link joining any pair. plain_language: A second trial pointed the same way on every measure and reached statistical significance on none of them. organism: Human tissue_or_cell_type: Untreated advanced non-small cell lung cancer experimental_model: Randomised controlled phase II trial with blinded central radiology review as the primary read limitations: Ninety-two patients randomised 61 to 31, with response read centrally. A higher rate of grade 3 or 4 adverse events occurred on the glucan arm. exposure: BTH1677 4 milligrams per kilogram weekly with bevacizumab, carboplatin and paclitaxel against the same backbone alone evidence_span: {"source_cache": "artifacts/glucan-research/29486797.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "7e4ff586490d7fdbefa5e817f7ee8b59c72e666bfb473620331f2fb178f46789", "start_char": 0, "end_char": 2024, "text_sha256": "7e4ff586490d7fdbefa5e817f7ee8b59c72e666bfb473620331f2fb178f46789"} [bg-p29486797] A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer. (2018). https://pubmed.ncbi.nlm.nih.gov/29486797/ DOI: 10.1186/s40425-018-0324-z
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards